Publication Information

{'id': 'https://openalex.org/W2734364973', 'doi': 'https://doi.org/10.1016/j.clinthera.2017.06.009', 'title': 'Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany', 'display_name': 'Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany', 'publication_year': 2017, 'publication_date': '2017-07-17', 'ids': {'openalex': 'https://openalex.org/W2734364973', 'doi': 'https://doi.org/10.1016/j.clinthera.2017.06.009', 'mag': '2734364973', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/28729087'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1016/j.clinthera.2017.06.009', 'pdf_url': 'http://www.clinicaltherapeutics.com/article/S0149291817307336/pdf', 'source': {'id': 'https://openalex.org/S185879095', 'display_name': 'Clinical Therapeutics', 'issn_l': '0149-2918', 'issn': ['0149-2918', '1879-114X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320990', 'host_organization_name': 'Elsevier BV', 'host_organization_lineage': ['https://openalex.org/P4310320990'], 'host_organization_lineage_names': ['Elsevier BV'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'hybrid', 'oa_url': 'http://www.clinicaltherapeutics.com/article/S0149291817307336/pdf', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5010721455', 'display_name': 'Nanxin Li', 'orcid': 'https://orcid.org/0009-0006-4412-0997'}, 'institutions': [{'id': 'https://openalex.org/I79463011', 'display_name': 'Analysis Group (United States)', 'ror': 'https://ror.org/044jp1563', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I79463011']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Nanxin Li', 'raw_affiliation_strings': ['Analysis Group Inc, Boston, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Analysis Group Inc, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I79463011']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5065311807', 'display_name': 'Keith A. Betts', 'orcid': 'https://orcid.org/0000-0002-3088-7453'}, 'institutions': [{'id': 'https://openalex.org/I79463011', 'display_name': 'Analysis Group (United States)', 'ror': 'https://ror.org/044jp1563', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I79463011']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Keith A. Betts', 'raw_affiliation_strings': ['Analysis Group Inc, Boston, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Analysis Group Inc, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I79463011']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5059830619', 'display_name': 'Andrew Messali', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I79463011', 'display_name': 'Analysis Group (United States)', 'ror': 'https://ror.org/044jp1563', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I79463011']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Andrew J. Messali', 'raw_affiliation_strings': ['Analysis Group Inc, Boston, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Analysis Group Inc, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I79463011']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5079729596', 'display_name': 'Martha Skup', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2948539688', 'display_name': 'AbbVie (United States)', 'ror': 'https://ror.org/02g5p4n58', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I2948539688']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Martha Skup', 'raw_affiliation_strings': ['AbbVie Inc, North Chicago, Illinois'], 'affiliations': [{'raw_affiliation_string': 'AbbVie Inc, North Chicago, Illinois', 'institution_ids': ['https://openalex.org/I2948539688']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5112105546', 'display_name': 'Vishvas Garg', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2948539688', 'display_name': 'AbbVie (United States)', 'ror': 'https://ror.org/02g5p4n58', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I2948539688']}], 'countries': ['US'], 'is_corresponding': True, 'raw_author_name': 'Vishvas Garg', 'raw_affiliation_strings': ['AbbVie Inc, North Chicago, Illinois'], 'affiliations': [{'raw_affiliation_string': 'AbbVie Inc, North Chicago, Illinois', 'institution_ids': ['https://openalex.org/I2948539688']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 2, 'corresponding_author_ids': ['https://openalex.org/A5112105546'], 'corresponding_institution_ids': ['https://openalex.org/I2948539688'], 'apc_list': {'value': 4210, 'currency': 'USD', 'value_usd': 4210, 'provenance': 'doaj'}, 'apc_paid': {'value': 4210, 'currency': 'USD', 'value_usd': 4210, 'provenance': 'doaj'}, 'fwci': 2.069, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 13, 'citation_normalized_percentile': {'value': 0.830287, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 87, 'max': 88}, 'biblio': {'volume': '39', 'issue': '8', 'first_page': '1618', 'last_page': '1627'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10200', 'display_name': 'Rheumatoid Arthritis Research and Therapies', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10200', 'display_name': 'Rheumatoid Arthritis Research and Therapies', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11616', 'display_name': 'Autoimmune and Inflammatory Disorders Research', 'score': 0.9988, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10185', 'display_name': 'Lymphoma Diagnosis and Treatment', 'score': 0.9974, 'subfield': {'id': 'https://openalex.org/subfields/2734', 'display_name': 'Pathology and Forensic Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/golimumab', 'display_name': 'Golimumab', 'score': 0.9360106}, {'id': 'https://openalex.org/keywords/abatacept', 'display_name': 'Abatacept', 'score': 0.8076477}, {'id': 'https://openalex.org/keywords/certolizumab-pegol', 'display_name': 'Certolizumab pegol', 'score': 0.7473074}, {'id': 'https://openalex.org/keywords/tocilizumab', 'display_name': 'Tocilizumab', 'score': 0.7298881}, {'id': 'https://openalex.org/keywords/tnf-inhibitor', 'display_name': 'TNF inhibitor', 'score': 0.6377672}, {'id': 'https://openalex.org/keywords/discontinuation', 'display_name': 'Discontinuation', 'score': 0.6128825}, {'id': 'https://openalex.org/keywords/rheumatism', 'display_name': 'Rheumatism', 'score': 0.5301512}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.97435653}, {'id': 'https://openalex.org/C2777226972', 'wikidata': 'https://www.wikidata.org/wiki/Q415343', 'display_name': 'Etanercept', 'level': 3, 'score': 0.9593178}, {'id': 'https://openalex.org/C2780132546', 'wikidata': 'https://www.wikidata.org/wiki/Q348260', 'display_name': 'Adalimumab', 'level': 3, 'score': 0.95778763}, {'id': 'https://openalex.org/C2781290027', 'wikidata': 'https://www.wikidata.org/wiki/Q413879', 'display_name': 'Golimumab', 'level': 4, 'score': 0.9360106}, {'id': 'https://openalex.org/C2779605438', 'wikidata': 'https://www.wikidata.org/wiki/Q2697833', 'display_name': 'Abatacept', 'level': 4, 'score': 0.8076477}, {'id': 'https://openalex.org/C2777575956', 'wikidata': 'https://www.wikidata.org/wiki/Q187255', 'display_name': 'Rheumatoid arthritis', 'level': 2, 'score': 0.76035464}, {'id': 'https://openalex.org/C2777138892', 'wikidata': 'https://www.wikidata.org/wiki/Q415264', 'display_name': 'Infliximab', 'level': 3, 'score': 0.75252795}, {'id': 'https://openalex.org/C2776215756', 'wikidata': 'https://www.wikidata.org/wiki/Q412909', 'display_name': 'Certolizumab pegol', 'level': 4, 'score': 0.7473074}, {'id': 'https://openalex.org/C2777178219', 'wikidata': 'https://www.wikidata.org/wiki/Q425154', 'display_name': 'Tocilizumab', 'level': 3, 'score': 0.7298881}, {'id': 'https://openalex.org/C2779722408', 'wikidata': 'https://www.wikidata.org/wiki/Q1536078', 'display_name': 'TNF inhibitor', 'level': 4, 'score': 0.6377672}, {'id': 'https://openalex.org/C2778715236', 'wikidata': 'https://www.wikidata.org/wiki/Q55622662', 'display_name': 'Discontinuation', 'level': 2, 'score': 0.6128825}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.60863173}, {'id': 'https://openalex.org/C2777489490', 'wikidata': 'https://www.wikidata.org/wiki/Q684924', 'display_name': 'Rheumatism', 'level': 2, 'score': 0.5301512}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.43717363}, {'id': 'https://openalex.org/C17991360', 'wikidata': 'https://www.wikidata.org/wiki/Q21173843', 'display_name': 'Tumor necrosis factor alpha', 'level': 2, 'score': 0.3069237}, {'id': 'https://openalex.org/C2780653079', 'wikidata': 'https://www.wikidata.org/wiki/Q412323', 'display_name': 'Rituximab', 'level': 3, 'score': 0.116288126}, {'id': 'https://openalex.org/C2779338263', 'wikidata': 'https://www.wikidata.org/wiki/Q208414', 'display_name': 'Lymphoma', 'level': 2, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D018501', 'descriptor_name': 'Antirheumatic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D014409', 'descriptor_name': 'Tumor Necrosis Factor-alpha', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D000069594', 'descriptor_name': 'Abatacept', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000069594', 'descriptor_name': 'Abatacept', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D018501', 'descriptor_name': 'Antirheumatic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001688', 'descriptor_name': 'Biological Products', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D001688', 'descriptor_name': 'Biological Products', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068800', 'descriptor_name': 'Etanercept', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000068800', 'descriptor_name': 'Etanercept', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005260', 'descriptor_name': 'Female', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005602', 'descriptor_name': 'France', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005858', 'descriptor_name': 'Germany', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016896', 'descriptor_name': 'Treatment Outcome', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014409', 'descriptor_name': 'Tumor Necrosis Factor-alpha', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006113', 'descriptor_name': 'United Kingdom', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1016/j.clinthera.2017.06.009', 'pdf_url': 'http://www.clinicaltherapeutics.com/article/S0149291817307336/pdf', 'source': {'id': 'https://openalex.org/S185879095', 'display_name': 'Clinical Therapeutics', 'issn_l': '0149-2918', 'issn': ['0149-2918', '1879-114X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320990', 'host_organization_name': 'Elsevier BV', 'host_organization_lineage': ['https://openalex.org/P4310320990'], 'host_organization_lineage_names': ['Elsevier BV'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28729087', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1016/j.clinthera.2017.06.009', 'pdf_url': 'http://www.clinicaltherapeutics.com/article/S0149291817307336/pdf', 'source': {'id': 'https://openalex.org/S185879095', 'display_name': 'Clinical Therapeutics', 'issn_l': '0149-2918', 'issn': ['0149-2918', '1879-114X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320990', 'host_organization_name': 'Elsevier BV', 'host_organization_lineage': ['https://openalex.org/P4310320990'], 'host_organization_lineage_names': ['Elsevier BV'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.79, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 36, 'referenced_works': ['https://openalex.org/W153249915', 'https://openalex.org/W1550247426', 'https://openalex.org/W1761742672', 'https://openalex.org/W1971610012', 'https://openalex.org/W1979364075', 'https://openalex.org/W1980521490', 'https://openalex.org/W1985063871', 'https://openalex.org/W2019258224', 'https://openalex.org/W2041427352', 'https://openalex.org/W2043124279', 'https://openalex.org/W2061326496', 'https://openalex.org/W2072810447', 'https://openalex.org/W2079590652', 'https://openalex.org/W2091055562', 'https://openalex.org/W2097291747', 'https://openalex.org/W2105840591', 'https://openalex.org/W2106914983', 'https://openalex.org/W2108305026', 'https://openalex.org/W2110056335', 'https://openalex.org/W2120393706', 'https://openalex.org/W2122265491', 'https://openalex.org/W2122890641', 'https://openalex.org/W2133028044', 'https://openalex.org/W2133915381', 'https://openalex.org/W2134704116', 'https://openalex.org/W2152721471', 'https://openalex.org/W2157770246', 'https://openalex.org/W2289495056', 'https://openalex.org/W2314052274', 'https://openalex.org/W2319957449', 'https://openalex.org/W2322147187', 'https://openalex.org/W2330158883', 'https://openalex.org/W2344924875', 'https://openalex.org/W3146223861', 'https://openalex.org/W4211111012', 'https://openalex.org/W4235790631'], 'related_works': ['https://openalex.org/W4232723785', 'https://openalex.org/W3107123570', 'https://openalex.org/W2953219636', 'https://openalex.org/W2415408788', 'https://openalex.org/W2240357112', 'https://openalex.org/W2205711752', 'https://openalex.org/W2141229429', 'https://openalex.org/W2133668754', 'https://openalex.org/W1980351720', 'https://openalex.org/W1922166444'], 'abstract_inverted_index': {'The': [0, 142, 234, 358], 'purpose': [1], 'of': [2, 11, 44, 53, 69, 79, 105, 111, 174, 182, 289, 335, 349, 372, 385], 'this': [3, 369], 'study': [4, 143, 166], 'was': [5, 195, 296, 323, 407], 'to': [6, 65, 189, 197, 283, 347, 402], 'assess': [7], 'the': [8, 36, 56, 165, 175, 183, 199, 287, 363, 377], 'real-world': [9], 'effectiveness': [10], 'patients': [12, 45, 290, 373], 'with': [13, 46, 213, 257, 326, 374], 'rheumatoid': [14], 'arthritis': [15], '(RA)': [16], 'who': [17], 'discontinued': [18], 'etanercept': [19, 112, 240, 386], 'treatment': [20, 148, 212, 220, 241], 'and': [21, 40, 60, 75, 99, 113, 133, 153, 158, 206, 228, 247, 271, 311, 345, 366, 381, 416], 'subsequently': [22], 'received': [23], 'another': [24, 80], 'tumor': [25], 'necrosis': [26], 'factor': [27], 'α': [28], '(TNF-α)': [29], 'inhibitor': [30, 82, 188], 'or': [31, 87, 89, 94, 409], 'a': [32, 51, 67, 90, 115, 162, 192, 214, 258, 327, 391], 'non-TNF-α': [33, 91, 154, 207, 229, 284, 314, 350, 403, 417], 'biologic': [34, 92, 117, 399], 'in': [35, 55, 135, 362, 376], 'United': [37, 57, 378], 'Kingdom,': [38, 58, 379], 'France,': [39, 59, 380], 'Germany.Medical': [41], 'record': [42], 'data': [43], 'RA': [47, 375], 'were': [48, 63, 122, 145, 168, 217, 242, 255, 360, 393], 'collected': [49], 'from': [50], 'panel': [52], 'rheumatologists': [54], 'Germany.': [61], 'Patients': [62], 'required': [64], 'have': [66, 76], 'diagnosis': [68], 'RA,': [70, 191], 'be': [71], '≥18': [72], 'years': [73], 'old,': [74], 'initiated': [77], 'use': [78, 104, 110], 'TNF-α': [81, 151, 176, 187, 204, 223, 252, 303, 337, 388, 414], '(adalimumab,': [83], 'certolizumab': [84], 'pegol,': [85], 'golimumab,': [86], 'infliximab)': [88], '(abatacept': [93], 'tocilizumab)': [95], 'between': [96, 172], 'January': [97], '2014': [98], 'May': [100], '2015': [101], 'after': [102, 383], 'discontinuing': [103, 109, 239], 'etanercept.': [106], 'Reasons': [107], 'for': [108, 238, 299], 'selecting': [114], 'second': [116, 215, 398], 'disease-modifying': [118], 'antirheumatic': [119], 'drug': [120], '(DMARD)': [121], 'described.': [123], 'Study': [124], 'outcomes': [125, 144, 167, 200], 'included': [126], 'European': [127], 'League': [128], 'Against': [129], 'Rheumatism': [130], '(EULAR)': [131], 'response': [132, 263, 295], 'change': [134, 275, 330], 'Clinical': [136], 'Disease': [137], 'Activity': [138], 'Index': [139], '(CDAI)': [140], 'score.': [141], 'compared': [146, 171], 'among': [147, 201], 'groups': [149, 221], '(ie,': [150], 'inhibitors': [152, 224, 253, 304, 338, 389, 415], 'biologics)': [155], 'using': [156], 'descriptive': [157], 'multivariable-adjusted': [159, 364], 'analyses.': [160], 'As': [161], 'secondary': [163, 193, 367], 'analysis,': [164], 'also': [169, 324], 'descriptively': [170], 'each': [173], 'inhibitors.': [177], 'Because': [178], 'adalimumab': [179, 300, 406], 'is': [180], 'one': [181], 'most': [184, 235], 'commonly': [185], 'used': [186], 'treat': [190], 'analysis': [194, 365, 371], 'conducted': [196], 'compare': [198], 'adalimumab,': [202], 'other': [203, 302, 336, 413], 'inhibitors,': [205], 'inhibitors.Patient': [208], 'characteristics': [209], 'before': [210], 'initiating': [211], 'DMARD': [216], 'similar': [218], 'across': [219], '(all': [222], '[n': [225, 231], '=': [226, 232, 280, 309, 320, 356], '296]': [227], 'biologics': [230, 315, 351], '276]).': [233], 'common': [236], 'reasons': [237], 'inadequate': [243], 'response,': [244], 'adverse': [245], 'effects,': [246], 'patient': [248], 'preference.': [249], 'After': [250], 'etanercept,': [251], 'overall': [254, 394], 'associated': [256, 325], 'significantly': [259, 331], 'lower': [260], 'EULAR': [261, 293], 'good': [262, 294], 'rate': [264], '(56.0%': [265], 'vs.': [266], '64.4%,': [267, 318], 'P': [268, 279, 308, 319, 342, 355], '<': [269, 343], '0.05)': [270, 344], 'smaller': [272], 'CDAI': [273, 328], 'score': [274, 329], '(-6.3': [276], 'vs': [277, 306, 317, 340, 353], '-7.3,': [278, 354], '.06)': [281], 'relative': [282, 401], 'biologics.': [285, 418], 'However,': [286], 'proportion': [288], 'achieving': [291], 'an': [292], 'numerically': [297], 'higher': [298], 'versus': [301, 313], '(61.1%': [305, 316], '51.6%,': [307], '0.11)': [310], 'comparable': [312, 346], '0.52).': [321], 'Adalimumab': [322], 'greater': [332], 'than': [333], 'that': [334, 348], '(-7.1': [339, 352], '-5.8,': [341], '0.79).': [357], 'results': [359], 'consistent': [361], 'analysis.In': [368], 'retrospective': [370], 'Germany,': [382], 'discontinuation': [384], 'treatment,': [387], 'as': [390, 397, 410, 412], 'class': [392], 'less': [395], 'effective': [396, 411], 'DMARDs': [400], 'biologics;': [404], 'however,': [405], 'more': [408]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2734364973', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2023, 'cited_by_count': 1}, {'year': 2021, 'cited_by_count': 3}, {'year': 2020, 'cited_by_count': 4}, {'year': 2019, 'cited_by_count': 2}, {'year': 2018, 'cited_by_count': 2}], 'updated_date': '2024-12-10T23:16:04.845486', 'created_date': '2017-07-21'}